Clinical trials: Prostate Cancer (Adenocarcinoma), open to volunteers
Prostate Cancer, Prostate Adenocarcinoma
Whole Versus Partial Gland Boost During Prostate SBRT
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
- Trial name
- NCT07574489
- Testing
- Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent
- Trial name
- Fezo-ADT (NCT06957691)
- Testing
- fezolinetant - reference formulation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shehzad Basaria, M.D.
Prostate Cancer (Adenocarcinoma)
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
The PARIS-BIO study evaluates whether a novel genomic biomarker, the PCAI ImmunoScore, can predict the response to neoadjuvant treatment with Darolutamide in patients with high-risk localized or locally advanced prostate cancer.
- Trial name
- PARIS-BIO (NCT07617272)
- Testing
- Darolutamide, Radical prostatectomy
- Where
- 2 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Region Stockholm
Prostate Adenocarcinoma, Prostate Cancer
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received…
- Trial name
- NCT03933670
- Testing
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging, MRI Ultrasound Fusion Guided Biopsy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Prostate Cancer (Adenocarcinoma)
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
- Trial name
- DINGO (NCT07552922)
- Testing
- Semi-structured Interview
- Where
- Australia
- Volunteers
- 24 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- HYDRA (NCT04945642)
- Testing
- High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer.
- Trial name
- NCT04175431
- Testing
- Positron Emission Tomography, Lymphadenectomy, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Washington
Urothelial Cancer, Bladder Cancer
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04923178
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Trial name
- DUAL-NK-PC (NCT07641049)
- Testing
- ETB-DualNK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Neoplams, Prostate Cancer (Adenocarcinoma)
Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention
This study will determine the feasibility and acceptability of a 12-week dyadic culinary nutrition program among Hispanic prostate cancer survivor/caregiver dyads using a randomized controlled trial design.
- Conditions
- Neoplams, Prostate Cancer (Adenocarcinoma), Cancer Survivors, Caregiver Burden
- Trial name
- CHEF (NCT07702864)
- Testing
- Cooking Healthy - Engaging Families (CHEF), Control
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Prostate Cancer, Prostate Adenocarcinoma
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Trial name
- NCT05751434
- Testing
- Exercise Therapy
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- City of Hope Medical Center
Urological Malignancies, Prostate Cancer
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles.
- Conditions
- Urological Malignancies, Prostate Cancer, Renal Cell Cancer, Bladder Cancer
- Trial name
- NCT04625556
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Yonsei University
Metastatic Prostate Cancer
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
- Trial name
- NCT06800313
- Testing
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Adenocarcinoma
INSPIRE: INnovative SABR for Prostate Cancer All IREland
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer.
- Trial name
- NCT07552168
- Testing
- Next generation Stereotactic Ablative Radiotherapy (SABR)
- Where
- 4 sites in Ireland, United Kingdom
- Volunteers
- 136 people
- Sponsor
- Cancer Trials Ireland
Prostate Adenocarcinoma
Personalized Optimization of Systematic Prostate Biopsy
Targeted biopsy combined systematic biopsy is the gold standard for diagnosis of prostate cancer. Excessive cores in systematic biopsy increases the risk of puncture trauma， bleeding and infection.
- Trial name
- NCT05998278
- Testing
- Personalized Optimization of Systematic Prostate Biopsy
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Fujian Medical University Union Hospital
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer, Prostate Adenocarcinoma
Customized TULSA-PRO Ablation Registry
This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
- Trial name
- CARE (NCT05001477)
- Testing
- TULSA Procedure
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Profound Medical Inc.
Breast Adenocarcinoma, Prostate Cancer (Adenocarcinoma)
Personalization of External Beam Radiation Therapy in Localised Tumours
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).
- Trial name
- MINIONS (NCT07047495)
- Testing
- prostate patient, breast patients
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Prostatic Neoplasms, Prostate Cancer
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland.
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT05616650
- Testing
- 18F-DCFPyL, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)